Active, not recruitingPhase 3NCT04908189
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Studying NON RARE IN EUROPE: Psoriatic arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Deucravacitinib(drug)
- Enrollment
- 729 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Local Institution - 0149, Mountain Brook, Alabama, United States
- Local Institution - 0212, Sacramento, California, United States
- Local Institution - 0188, Whittier, California, United States
- Local Institution - 0192, Skokie, Illinois, United States
- Local Institution - 0203, Hopkinsville, Kentucky, United States
- Local Institution - 0195, Baton Rouge, Louisiana, United States
- Local Institution - 0169, Cumberland, Maryland, United States
- Local Institution - 0034, Okemos, Michigan, United States
- Local Institution - 0133, Eagan, Minnesota, United States
- Local Institution - 0109, Hattiesburg, Mississippi, United States
- Local Institution - 0108, New York, New York, United States
- Local Institution - 0186, Rochester, New York, United States
- Local Institution - 0196, Charlotte, North Carolina, United States
- Local Institution - 0180, Cleveland, Ohio, United States
- Local Institution - 0189, Oklahoma City, Oklahoma, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04908189 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Psoriatic arthritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07290036A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in AdultsUCB Biopharma SRL
- RECRUITINGNANCT06382051Modifying PEST for Psoriatic Arthritis ScreeningNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT06176508Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic ArthritisHansoh BioMedical R&D Company
- ENROLLING BY INVITATIONNANCT06176586Mat Pilates Exercise Program in Patients With Axial Psoriatic ArthritisIzmir Katip Celebi University
- RECRUITINGNCT06437392Evaluation of Sarcopenia and Related Factors in Patients Diagnosed With Psoriatic ArthritisAnkara City Hospital Bilkent
- RECRUITINGNCT07277491Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease ActivityCairo University
- RECRUITINGNCT03768271APACHE Cohort (A Psoriatic Arthritis CoHort)Assistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE3NCT03671148A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)AbbVie
See all trials for NON RARE IN EUROPE: Psoriatic arthritis →